Telotristat etiprate

Drug Profile

Telotristat etiprate

Alternative Names: LP-778914 (free base); LX 1032; LX 1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Telotristat ethyl hippurate; Xermelo

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin modulators; TPH1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 06 Mar 2017 Chemical structure information added
  • 01 Mar 2017 Launched for Malignant carcinoid syndrome (Adjunctive treatment, Treatment-experienced) in USA (PO)
  • 28 Feb 2017 Registered for Malignant carcinoid syndrome (Adjunctive treatment, Treatment-experienced) in USA (PO, Tablet) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top